Nanoparticles in oncology: The new theragnostic molecules

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 7, 2011, Pages 669-686

  Allegra, Alessandro ^a   Penna, Giuseppa ^a   Alonci, Andrea ^a   Rizzo, Vincenzo ^a   Russo, Sabina ^a   Musolino, Caterina ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Drug delivery; Gene therapy; Imaging; Nanoparticles; Nanotechnology; Nanovectors; Theragnostic molecules

Indexed keywords

4 (4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CASTOR OIL; CHOLESTEROL CONJUGATED CARBOXYMETHYLCURDLAN; CISPLATIN; CURCUMIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FOLIC ACID; GOLD NANOPARTICLE; LIPOSOME; MECAPTO POLYETHYLENE GLYCOL; METHOTREXATE; NANODIAMOND; NANOPARTICLE; PACLITAXEL; PERIFOSINE; PHOTOSENSITIZING AGENT; POLYGLACTIN; QUANTUM DOT; RADIOISOTOPE; RAPAMYCIN; RETINOIC ACID; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINC PHTHALOCYANINE DISULPHIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMELANOTIC MELANOMA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER DIAGNOSIS; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DNA DAMAGE; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; DRUG SOLUBILITY; DRUG SPECIFICITY; DRUG STABILITY; DRUG STRUCTURE; DRUG TARGETING; GENE THERAPY; HEAD AND NECK CANCER; HUMAN; IMMUNE SYSTEM; IONIZING RADIATION; LIVER CANCER; LUNG CANCER; MULTIPLE MYELOMA; NANOTECHNOLOGY; NEPHROTOXICITY; NONHUMAN; OVARY ADENOCARCINOMA; OVARY CANCER; PARTICLE SIZE; PHASE 1 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; PHYSICAL CHEMISTRY; RADIATION DOSE; REVIEW; SQUAMOUS CELL CARCINOMA; UNSPECIFIED SIDE EFFECT;

EID: 80051729412     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152011796817682     Document Type: Review

References (238)

1. Ferrari, M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer, 2005, 5, 161-171.
2. Grobmyer, S.R.; Iwakuma, N.; Sharma, P.; Moudgil, B.M. What is cancer Nanotechnology? In: Cancer Nanotechnology, Methods in Molecular Biology; 624. Springer Science+Business LLC 2010; Chapter 1, pp. 1-9
3. Vertegel, A.A.; Siegel, R.W.; Dordick, J.S. Silica nanoparticle size influences the structure and enzymatic activity of adsorbed lysozyme. Langmuir, 2004, 20, 6800-6807.
4. Wang, M.; Thanou, M. Targeting nanoparticles to cancer. Pharmacological Research, 2010, 62, 90-99.
5. Cuenca, A.G.; Jiang, H.; Hochwald, S.N.; Delano, M.; Cance, W.G.; Grobmyer, S.R. Emerging implications of nanotechnology on cancer diagnostic and therapeutics. Cancer, 2006, 107, 459-466.
6. Santra, S.; Kaittanis, C.; Grimm, J.; Perez, J.M. Drug/dye-loaded, multifunctional iron oxide nanoparticles for combined targeted cancer therapy and dual optical/magnetic resonance imaging. Small, 2009, 5, 1862-1868.
7. Kim, K.; Kim, J.H.; Park, H.; Kim, Y.S.; Nam, H.; Lee, S.; Park, J.H.; Park, R.W.; Kim, I.S.; Choi, K.; Kim, S.Y., Park, K.; Kwon, I.C. Tumor-homing multifunctional nanoparticles for cancer theragnosis: simultaneous diagnosis, drug delivery, and therapeutic monitoring. J Control. Release, 2010, Apr 24 Epub ahead of print
8. Huang, X.; Jain, P.K.; El-Sayed, I.H.; El-Sayed, M.A. Gold nanoparticles: interesting optical properties and recent applications in cancer diagnostics and therapy. Nanomed., 2007, 2, 681-693.
9. Peer, D.; Karp, J.M.; Hong, S.; Farokhzad, O.C.; Margalit, R.; Langer, R. Nanocarries as an emerging platform for cancer therapy. Nat. Nanotechnol., 2007, 2, 751-760.
10. Robert, N.J.; Vogel, C.L.; Henderson, I.C.; Sparano, J.A.; Moore, M.R.; Silverman, P.; Overmoyer, B.A.; Shapiro, C.L.; Park, J.W.; Colbern, G.T.; Winer, E.P.; Gabizon, A.A. The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. Semin. Oncol., 2004, 31, 106-146.
11. Li, L.; Gao, F.P.; Tang, H.B.; Bai, Y.G.; Li, R.F.; Li, X.M.; Liu, L.R.; Wang, Y.S.; Zhang, Q.Q. Self-assembled nanoparticles of cholesterol-conjugated carboxymethyl curdlan as a novel carrier of epirubicin. Nanotechnology, 2010, 21(26), 265601.
12. Chiu, G.N.; Wong, M.Y.; Ling, L.U.; Shaikh, I.M.; Tan, K.B.; Chaudhury, A.; Tan, B.J. Lipid-based nanoparticulate systems for the delivery of anti-cancer drug cocktails: implications on pharmacokinetics and drug toxicities. Curr. Drug Metab., 2009, 10, 861-874.
13. Miele, E.; Spinelli, G.P.; Tomao, F.; Tomao, S. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int. J. Nanomed., 2009, 4, 99-105.
14. Lobo, C.; Lopes, G.; Baez, O.; Castrellon, A.; Ferrell, A.; Higgins, C.; Hurley, E.; Hurley, J.; Reis, I.; Richman, S.; Seo, P.; Silva, O.; Slingerland, J.; Tukia, K.; Welsh, C.; Gluck, S. Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Res. Treat., 2010, 123(2), 427-435.
15. Shive, M.S.; Anderson, J.M. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev., 1997, 28(1), 5-24.
16. Jain, R.A. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials, 2000, 21(23), 2475-2490.
17. Pamujula, S.; Hazari, S.; Bolden, G.; Graves, R.A.; Chinta, D.M.; Dash, S.; Kishore, V.; Mandal, T.K. Preparation and in-vitro/ in-vivo evaluation of surface-modified poly (lactide-co-glycolide) fluorescent nanoparticles. J. Pharm. Pharmacol., 2010, 62(4), 422-429.
18. Ma, Y.; Zheng, Y.; Liu, K.; Tian, G.; Tian, Y.; Xu, L.; Yan, F.; Huang, L.; Mei, L.Nanoparticles of Poly(Lactide-Co-Glycolide)-da- Tocopheryl Polyethylene Glycol 1000 Succinate Random Copolymer for Cancer Treatment. Nanoscale Res. Lett., 2010, 5(7), 1161-1169.
19. Ling, Y.; Huang, Y.S. Preparation and release efficiency of poly (lactic-co-glycolic) acid nanoparticles for drug loaded paclitaxel. In: Peng Y, Wen X, editors. 7th Asian-Pacific Conference on Medical and Biological Engineering APCMBE, IFMBE Proceedings. Berlin, Heidelberg: Springer; 2008; pp. 514-517.
20. Fischer, J.R.; Harkin, K.R.; Freeman, L.C. Concurrent administration of water-soluble vitamin E can increase the oral bioavailability of cyclosporine A in healthy dogs. Vet. Ther., 2002, 3, 465-473.
21. Dintaman, J.M.; Silverman, J.A. Inhibition of P-glycoprotein by Dalpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm. Res., 1999, 16, 1550-1556.
22. Yu, L.; Bridgers, A.; Polli, J.; Vicker, A.; Long, S.; Roy, A.; Winnike, R.; Coffin, M. Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm. Res., 1999, 16, 1812-1817.
23. Youk, H.J.; Lee, E.; Choi, M.K.; Lee, Y.J.; Chung, J.H.; Kim, S.H.; Lee, C.H.; Lin, S.J. Enhanced anticancer efficacy of alphatocopheryl succinate by conjugation with polyethylene glycol. J. Control. Release, 2005, 107, 43-52.
24. Constantinou, C.; Papas, A.; Constantinou, A.I. Vitamin E and cancer: an insight into the anticancer activities of vitamin E isomers and analogs. Int. J. Cancer, 2008, 123, 739-752.
25. Neuzil, J.; Tomasetti, M.; Zhao, Y.; Dong, L.F.: Birringer, M.; Wang, X.F.; Low, P.; Wu, K.; Salvatore, B.A.; Ralph, S.J. Vitamin E analogs, a novel group of "mitocans," as anticancer agents: the importance of being redox-silent. Mol. Pharmacol., 2007, 71, 1185-1199.
26. Gan, C.W.; Chien, S.; Feng, S.S. Nanomedicine: enhancement of chemotherapeutical efficacy of docetaxel by using a biodegradable nanoparticle formulation. Curr. Pharm. Des., 2010, 16(21), 2308-2320.
27. Peng, X.H.; Qian, X.; Mao, H.; Wang, A.Y.; Chen, Z.G.; Nie, S.; Shin, D.M. Targeted magnetic iron oxide nanoparticles fot tumor imaging and therapy. Int. J. Nanomed., 2008, 3, 311-321.
28. Jain, P.K.; Huang, X.; El-Sayed, I.H.; El-Sayed, M.A. Noble metals on the nanoscale: optical and photothermal properties and some applications in imaging, sensing, biology, and medicine. Acc. Chem. Res., 2008, 41(12), 1578-1586.
29. Daniel, M.C.; Astruc, D. Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology. Chem. Rev., 2004, 104(1), 293-346.
30. Melancon, M.P.; Lu, W.; Yang, Z.; Zhang, R.; Cheng, Z.; Elliot, A.M.; Stafford, J.; Olson, T.; Zhang, J.Z.; Li, C. In vitro and in vivo targeting of hollow gold nanoshells directed at epidermal growth factor receptor for photothermal ablation therapy. Mol. Cancer Ther., 2008, 7(6), 1730-1739.
31. Chen, Y.H.; Tsai, C.Y.; Huang, P.Y.; Chang, M.Y.; Cheng, P.C.; Chou, C.H.; Chen, D.H.; Wang, C.H.; Shiau, A.L.; Wu, C.L. Methotrexate conjugated to gold nanoparticles inhibits tumor growth in a syngeneic lung tumor model. Mol. Pharm., 2007, 4, 713-722.
32. Dreaden, E.C.; Mwakwari, S.C.; Sodji, Q.H.; Oyelere, A.K.; El- Sayed, M.A. Tamoxifen-poly(ethylene glycol)-thiol gold nanoparticle conjugates: enhanced potency and selective delivery for breast cancer treatment. Bioconjug. Chem., 2009, 20, 2247-2253.
33. Brown, S.D.; Nativo, P.; Smith, J.A.; Stirling, D.; Edwards, P.R.; Venugopal, B.; Flint, D.J.; Plumb, J.A.; Graham, D.; Wheate, N.J. Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. J. Am. Chem. Soc., 2010, 132, 4678-4684.
34. Curley, S.A.; Cherukuri, P.; Briggs, K.; Patra, C.R.; Upton, M.; Dolson, E.; Mukherjee, P. Noninvasive radiofrequency fieldinduced hyperthermic cytotoxicity in nanoparticles. J. Exp. Ther. Oncol., 2008, 7, 313-326.
35. Cherukuri, P.; Curley, S.A. Use of nanoparticles for targeted, noninvasive thermal destruction of malignant cells. Methods Mol. Biol., 2010, 624, 359-373.
36. Hainfeld, J.F.; Dilmanian, F.A.; Slatkin, D.N.; Smilowitz, H.M. Radiotherapy enhancement with gold nanoparticles. J. Pharm. Pharmacol., 2008, 60, 977-985.
37. Butterworth, K.T.; Coulter, J.A.; Jain, S.; Forker, J.; McMahon, S.J.; Schettino, G.; Prise, K.M.; Currel, F.J.; Hirst, D.G. Evaluation of cytotoxicity and radiation enhancement using 1.9 nm gold particles: potential application for cancer therapy. Nanotechnology, 2010, 21, 295101-295109.
38. Kong, G.; Braun, R.D.; Dewhirst, M.W. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res., 2000, 60(16), 4440-4445.
39. Zhang, F.; Skoda, M.W.; Jacobs, R.M.; Zorn, S.; Martin, R.A.; Martin, C.M.; Clark, G.F.; Goerigk, G.; Schreiber, F. Gold nanoparticles decorated with oligo(ethylene glycol) thiols: protein resistance and colloidal stability. J. Phys. Chem. A., 2007, 111(49), 12229-12237.
40. Otsuka, H.; Nagasaki, Y.; Kataoka, K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv. Drug. Deliv. Rev., 2003, 55(3), 403-419.
41. Niidome, T.; Yamagata, M.; Okamoto, Y.; Akiyama, Y.; Takahashi, H.; Kawano, T.; Katayama, Y.; Niidome, Y. PEG-modified gold nanorods with a stealth character for in vivo applications. J. Control Release, 2006, 114(3), 343-347.
42. Paciotti, G.F.; Myer, L.; Weinreich, D.; Goia, D.; Pavel, N.; McLaughlin, R.E.; Tamarkin, L. Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv., 2004, 11(3), 169-183.
43. De Jong, W.H.; Hagens, W.I.; Krystek, P.; Burger, M.C.; Sips, A.J.; Geertsma, R.E. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials., 2008, 29(12), 1912-1919.
44. Choi, H.S.; Liu, W.; Misra, P.; Tanaka, E.; Zimmer, J.P.; Ipe, B.; Bawendi, M.G.; Frangioni, J.V. Renal clearance of quantum dots. Nat. Biotechnol., 2007, 25(10), 1165-1170.
45. Decuzzi, P.; Ferrari, M. The adhesive strength of non-spherical particles mediated by specific interactions. Biomaterials., 2006, 27(30), 5307-5314.
46. Fujita, T.; Nishikawa, M.; Ohtsubo, Y.; Ohno, J.; Takakura, Y.; Sezaki, H.; Hashida, M. Control of in vivo fate of albumin derivatives utilizing combined chemical modification. J. Drug Target., 1994, 2(2), 157-165.
47. Torchilin, V.P.; Omelyanenko, V.G.; Papisov, M.I.; Bogdanov, A.A. Jr.; Trubetskoy, V.S.; Herron, J.N.; Gentry, C.A. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim. Biophys. Acta., 1994, 1195(1), 11-20.
48. Chouly, C.; Pouliquen, I.; Lucet, I.; Jeune, J.J.; Jallet, P. Development of superparamagnetic nanoparticles for MRI: effect of particle size, charge and surface nature on biodistribution. J. Microencapsul., 1996, 13, 245-255.
49. Sun, C.; Lee, J.S.; Zhang, M. Magnetic nanoparticles in MR imaging and drug delivery. Adv. Drug Deliv. Rev., 2008, 60(11), 1252-1265.
50. Hobbs, S.K.; Monsky, W.L.; Yuan, F.; Roberts, W.G.; Griffith, L.; Torchilin, V.P.; Jain, R.K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Nat. Acad. Sci. USA., 1998, 95(8), 4607-4612.
51. Von Maltzahn, G.; Park, J.H.; Agrawal, A.; Bandaru, N.K.; Das, S.K.; Sailor, M.J.; Bhatia, S.N. Computationally guided photothermal tumor therapy using long-circulating gold nanorod antennas. Cancer Res., 2009, 69, 3892-3900.
52. Wolinsky, J.B.; Grinstaff, M.W. Therapeutic and diagnostic applications of dendrimers for cancer treatment. Adv. Drug Deliv. Rev., 2008, 60, 1037-1055.
53. Barth, R.F.; Coderre, J.A.; Vicente, M.G.H.; Blue, T.E. Boron neutron capture therapy of cancer: current status and future prospects. Clin. Cancer Res., 2005, 11, 3987-4002.
54. Shi, X.; Wang, S.; Meshinchi, S.; Van Antwerp, M.E.; Bi, X.; Lee, I.; Baker, J.R. Jr. Dendrimer-entrapped gold nanoparticles as a platform for cancer-cell targeting and imaging. Small 2007, 3, 1245-1252.
55. van Haandel, L.; Stobaugh, J.F. Bioanalytical method development for a generation 5 polyamidoamine folic acid methotrexate conjugated nanoparticle. Annal Bioanal. Chem., 2010, 397(5), 1841-1852.
56. Lu, J.; Liong, M.; Li, Z.; Zink, J.I.; Tamanoi, F.; Biocompatibility, Biodistribution, and Drug-Delivery Efficiency of Mesoporous Silica Nanoparticles for Cancer Therapy in Animals. Small. 2010, 6(16), 1794-1805.
57. Kleps, I.; Ignat, T.; Miu, M.; Craciunoiu, F.; Trift, M.; Simion, M.; Bragaru, A.; Dinescu, A. Nanostructured silicon particles for medical applicartions. J. Nanosci Nanotechnology, 2010, 10, 2694-700.
58. Bae, Y.; Kataoka, K. Inteligent polymeric micelles rom functional poly(ethylene glycol)-poly(amino acid) block copolymers. Adv. Drug Deliver. Rev., 2009, 61, 768-784.
59. Nishiyama, N.; Kataoka, K. Current state, achievements, and future prospects of polymeric micelles as nanocarries for drug and gene delivery. Pharmacol. Ther., 2006, 112, 630-648.
60. Lee, H.; Fonge, H.; Hoang, B.; Reilly, R.M.; Allen, C.A. The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. Molecular Pharmaceutics, 2010, 7, 1195-1208.
61. Haeth, J.R.; Davis, M.E. Nanotechnology and cancer. Annu. Rev. Med., 2008, 59, 251-265.
62. Kawasaki, E.S.; Player, A. Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer. Nanomedicine, 2005, 1, 101-109.
63. Kim, K.Y. Nanotechnology platforms and physiological challenges for cancer therapeutics. Nanomedicine, 2007, 3, 103-110.
64. Sahoo, S.K.; Parveen, S.; Panda, J.J. The present and future of nanotechnology in human health care. Nanomedicine, 2007, 3, 20-31.
65. Koo, O.M.; Rubinstein, I.; Onyuksel, H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine, 2005, 1, 193-212.
66. Forrest, M.L.; Kwon, G.S. Clinical developments in drug delivery nanotechnology Adv. Drug Deliv. Rev., 2008, 60, 861-862.
67. Bhavsar, M.D.; Tiwari, S.B.; Amiji, M.M. Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design. J. Control. Release, 2006, 110(2), 422-430.
68. Hochwald, S.N. Molecular-targeted therapy for cancer nanotechnology. In: Cancer Nanotechnology, Methods in Molecular Biology 624, Springer Science+Business Media, LLC 2010, Grobmyer SR, Moudgil BM (eds.), Chapter 2, pp.11-23.
69. Ruoslahti, E.; Bhatia, S.N.; Sailor, M.J. Targeting of drugs and nanoparticles to tumors. J. Cell. Biol., 2010, 188, 759-768.
70. Lyer, S.; Tietze, R.; Jurgons, R.; Struffert, T.; Engelhorn, T.; Schreiber, E.; Dörfler, A.; Alexiou, C. Visualisation of tumour regression after local chemotherapy with magnetic nanoparticles - a pilot study. Anticancer Res., 2010, 30(5),1553-1557.
71. Hua, M.Y.; Yang, H.W.; Chuang, C.K., Tsai, R.Y.; Chen, W.J.; Chuang, K.L.; Chang, Y.H.; Chuang, H.C.; Pang, S.T. Magneticnanoparticle- modified paclitaxel for targeted therapy for prostate cancer. Biomaterials., 2010, 31(28), 7355-7363.
72. Lowery, A.R.; Gobin, A.M.; Day, E.S.; Halas, N.J.; West, J.L. Immunonanoshells for targeted photothermal ablation of tumor cells. Int. J. Nanomedicine, 2006, 1(2), 149-154.
73. Chen, J.Y.; Wang, D.L.; Xi, J.F.; Au, L.; Siekkinen, A.; Warsen, A.; Li, Z.Y.; Zhang, H.; Xia, Y.N.; Li, X.D. Immuno gold nanocages with tailored optical properties for targeted photothermal destruction of cancer cells. Nano Lett., 2007, 7(5), 1318-1322.
74. Lu, W.; Xiong, C.; Zhang, G.; Huang, Q.; Zhang, R.; Zhang, J.Z.; Li, C. Targeted photothermal ablation of murine melanomas with melanocyte-stimulating hormone analog-conjugated hollow gold nanospheres. Clin. Cancer Res., 2009, 15(3), 876-886.
75. Garg, A.; Tisdale, A.W.; Haidari, E.; Kokkoli, E. Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin- mimetic peptide. Int. J. Pharm., 2009, 366, 201-210.
76. Laginha, K.M.; Moase, E.H.; Yu, N.; Huang, A.; Allen, T.M. Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer. J. Drug Target., 2008, 16, 605-610.
77. Rothdiener, M.; Beuttler, J.; Messerschmidt, S.K.E.; Kontermann, R.E. Antibody targeting of nanoparticles to Tumor-specific receptors: Immunoliposomes. In: Cancer Nanotechnology, Methods in Molecular Biology 624, Grobmyer SR, Moudgil BM (eds.), Springer Science +Business Media LLC 2010, 20, pp. 295-308.
78. Chen, Y.; Zhu, X.; Zhang, X.; Liu, B.; Huang, L. Nanoparticles modified with tumor-targheting scFv deliver siRNA and miRNA for cancer therapy. Mol. Ther., 2010, 18(9), 1650-1656.
79. Li, N.; Yang, X.; Zhai, G.; Li, L. Multifunctional pluronic/poly (ethylenimine) nanoparticles for anticancer drug. J. Coll. Inter. Sci., 2010, 350, 117-125.
80. Rosenholm, J.M.; Peuhu, E.; Bate-Eya, L.T.; Eriksson, J.E.; Sahlgren, C.; Lindén, M. Cancer-cell-specific induction of apoptosis using mesoporous silica nanoparticles as drug-delivery vectors. Small., 2010, 6(11), 1234-1241.
81. Agemy, L.; Sugahara, K.N.; Kotamraju, V.R.; Gujraty, K.; Girard, O.M.; Kono, Y.; Mattrey, R.F.; Park, J.H.; Sailor, M.J.; Jimenez, A.I.; Cativiela, C.; Zanuy, D.; Sayago, F.J.; Aleman, C.; Nussinov, R.; Ruoslahti, E. Nanoparticle-induced vascular blockade in human prostate cancer. Blood, 2010, 116(15), 2847-2856.
82. Sugahara, K.N.; Teesalu, T.; Karmatli, P.P.; Kotamraju, V.R.; Agemy, L.; Greenwald, D.R.; Ruoslahti, E. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science, 2010, 328, 1031-1035.
83. Hu, C.M.; Zhang, L. Therapeutic nanoparticles to combat cancer drug resistance. Curr. Drug. Metab., 2009, 10, 836-841.
84. Cheng, J.; Wu, W.W.; Chen, B.A.; Gao, F.; Xu, W.; Gao, C.; Ding, J.; Sun, Y.; Song, H.; Bao, W.; Sun, X.; Xu, C.; Chen, W.; Chen, N.; Liu, L.; Xia, G.; Li, X.; Wang, X. Effect of magnetic nanoparticles of Fe3O4 and 5-bromotetrandrine on reversal of multidrug resistance in K562/A02 leukemic cells. Int. J. Nanomedicine, 2009, 4, 209-216.
85. Chen, B.A.; Cheng, J.; Shen, M.F.; Gao, F.; Xu, W.L.; Ding, J.H.; Gao, C.; Sun, X.C.; Li, G.H.; Chen, W.J.; Liu, L.J.; Li, X.M.; Wang, X.M. Effects of magnetic nanoparticle of fe(3)o(4) and 5- Bromotetrandrin on apoptosis of K562/A02 leukemic cells induced by daunorubicin. Zhongguo Shi Yan Xue Ye Xue Za Zhi., 2009, 17(1), 54-59.
86. Wu, Y.N.; Chen, B.A.; Cheng, J.; Gao, F.; Xu, W.L.; Ding, J.H.; Gao, C.; Sun, X.C.; Li, G.H.; Chen, W.J.; Liu, L.J.; Li, X.M.; Wang, X.M. Reversal of multidrug resistance in xenograft nude-mice by magnetic Fe(3)O(4) nanoparticles combined with daunorubicin and 5-bromotetrandrine. Zhongguo Shi Yan Xue Ye Xue Za Zhi., 2009, 17(1), 60-64.
87. Chen, Y.; Bathula, S.R.; Li, J.; Huang, L. Multifunctional nano particles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J Biol Chem., 2010, 285(29), 22639-22650.
88. Dong, X.; Mumper, R.J. Nanomedicinal strategies to treat multidrug-resitant tumors: current progress. Nanomedicine, 2010, 5, 597-615.
89. Zhang, H.; Jiang, H.; Wang, X.; Chen, B. Reversion of multidrug resistance in tumor by biocompatible nanomaterials. Mini Rev. Med. Chem., 2010, 10(8), 737-745.
90. Kurmi, B.D.; Kayat, J.; Gajbhiye, V.; Tekade, R.K.; Jain, N.K. Micro- and nanocarrier-mediated lung targeting. Expert Opin. Drug Deliver., 2010, 7, 781-794.
91. Brzoska, M.; Langher, K.; Coester, C.; Loitsch, S.; Wagner, T.O.; Mallinckrodt, C. Incorporation of biodegradable nanoparticles into human airway epithelium cell-in vitro study of the suitability as a vehicle for drug or gene delivery in pulmonary diseases. Biochem. Biophys. Res. Commun., 2004, 318, 562-570.
92. Mykhaylyk, O.; Dudchenko, N.; Dudchenko, A. Doxorubicin magnetic conjugate targeting upon intravenous injection into mice high gradient magnetic field inhibits the clearance of nanoparticles from the blood. J. Magn. Magn. Mater., 2005, 293, 473-482.
93. Tseng, C.I.; Wanga, T.W.; Dong, G.C.; Wu, S.; Young, T.H.; Shieh, M.J.; Lou, P.J.; Lin, F.H. Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting. Biomaterials, 2007, 28, 3996-4005.
94. Liu, K.K.; Zheng, W.W.; Wang, C.C.; Chiu, Y.C., Cheng, C.L.; Lo, Y.S.; Chen, C.; Chao, J.I. Covalent linkage of nanodiamondpaclitaxel for drug delivery and cancer therapy. Nanotechnology, 2010, 21(31), 315106.
95. Zhang, J.Q.; Lu, B. Studies on lung targeted niosomes of carboplatin. Acta Pharm. Sin., 2001, 36, 303-306.
96. Park, I.K.; Tran, T.H.; Oh, I.H.; Cho, K.J.; Huh, K.M.; Lee, Y.K. Ternary biomolecular nanoparticles for targeting of cancer cells and anti-angiogenesis. European Journal of Pharmaceutical Sciences, 2010, 41, 148-155.
97. Paciotti, G.F.; Kingston, D.G.; Tamarkin, L. Colloidal gold nanoparticles: a novel nanoparticle platform for developing multifunctional tumor-targeted drug delivery vectors. Drug Dev. Res., 2006, 67, 47-54.
98. Fadee, G.; Mondalek, F.G.; Ponnurangam, S.; Govind, J.; Houchen, C.; Anant, S.; Pantazis, P.; Ramanujam, R.P. Inhibition of angiogenesis- and inflammation-inducing factors in human colon cancer cells in vitro and in ovo by free and nanoparticle-encapsulated redox dye, DCPIP. J. Nanobiotechnology, 2010, 8, 17.
99. Cervin, C.; Tinzl, M.; Johnsson, M.; Abrahamsson, P.A.; Tiberg, F.; Dizeyi, N. Properties and effects of a novel liquid crystal nanoparticle formulation of docetaxel in a prostate cancer mouse model. Eur. J. Pharm. Sci., 2010, 41(2), 369-375.
100. Orive, G.; Ali, O.A.; Anitua, E.; Pedraz, J.L.; Emerich, D.F. Biomaterial-based technologies for brain anti-cancer therapeutics and imaging. Biochim. Biophys. Acta., 2010, 1806(1), 96-107.
101. Petrelli, F.; Borgonovo, K.; Barni, S. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel. Expert Opin. Pharmacother., 2010, 11(8), 1413-1432.
102. Paraskar, A.S.; Soni, S.; Chin, K.T.; Chaudhuri, P.; Muto, K.W.; Berkowitz, J.; Handlogten, M.W.; Alves, N.J.; Bilgicer, B.; Daniela, M.; Dinulescu, D.M.; Mashelkar, R.A.; Sengupta, S. Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy. PNAS, 2010, 28, 12435-12440.
103. Patra, C.R.; Bhattacharya, R.; Mukherjee, P. Fabrication and functional characterization of goldnanoconjugates for potential application in ovarian cancer. J. Mater. Chem., 2010, 20(3), 547-554.
104. Yallapu, M.M.; Gupta, B.K.; Jaggi, M.; Chauhan, S.C. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. J. Colloid Interface Sci., 2010, 351(1), 19-29.
105. Maeng, J.H.; Lee, D.H.; Jung, K.H.; Bae, Y.H.; Park, I.S.; Jeong, S.; Jeon, Y.S.; Shim, C.K.; Kim, W.; Kim, J.; Lee, J.; Lee, Y.M.; Kim, J.H.; Kim, W.H.; Hong, S.S. Multifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancer. Biomaterials., 2010, 31(18), 4995-5006.
106. Uckun, F.M.; Dibirdik, I.; Qazi, S.; Yiv, S. Therapeutic nanoparticle constructs of a JAK3 tyrosine kinase inhibitor against human Blineage ALL cells. Arzneimittelforschung., 2010, 60(4), 210-217.
107. Jing, H.; Wang, J.; Yang, P.; Ke, X.; Xia, G.; Chen, B. Magnetic Fe3O4 nanoparticles and chemotherapy agents interact synergistically to induce apoptosis in lymphoma cells. Int. J. Nanomedicine., 2010, 5, 999-1004.
108. Singh, A.T.; Evens, A.M.; Anderson, R.J.; Beckstead, J.A.; Sankar, N.; Sassano, A.; Bhalla, S.; Yang, S.; Platanias, L.C.; Forte, T.M.; Ryan, R.O.; Gordon, L.I. All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma. Br. J. Haematol., 2010, 150(2), 158-69.
109. Cirstea, D.; Hideshima, T.; Rodig, S.; Santo, L.; Pozzi, S.; Vallet, S.; Ikeda, H.; Perrone, G.; Gorgun, G.; Patel, K.; Desai, N.; Sportelli, P.; Kapoor, S.; Vali, S.; Mukherjee, S.; Munshi, N.C.; Anderson, K.C.; Raje, N. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol. Cancer. Ther., 2010, 9(4), 963-975.
110. Stiti, M.; Cecchi, A.; Rami, M.; Abdaoui, M.; Barragan-Montero, V.; Scozzafava, A.; Guari, Y.; Winum, J-Y.; Supuran, C.T. Carbonic anhidrase inhibitor coated gold nanoparticles selectively inhibit the tumor-associated isoform IX over the cytosolic isozymes I and II. J. Am. Chem. Soc., 2008, 130, 16130-16131.
111. Saada, M-C.; Montero, J-L.; Vullo, D.; Scozzafava, A.; Winum, JY.; Supuran, C.T. Carbonic anhidrase activators: gold nanoparticles coated with derivatized histamine, histidine, and carnosine show enhanced activatory effects on several mammalian isoforms. Journal of Medicinal Chemistry, 2011, 54, 1170-1177.
112. Supuran, C.T. Carbonic anhydrases: novel therapeutic applications for inhibitors and activatrs. Nature Reviews. 2008, 7, 168-181.
113. Salerno, M.; Cenni, E.; Fotia, C.; Avnet, S.; Granchi, D.; Castelli, F.; Micieli, D.; Pignatello, R,; Capulli, M.; Rucci, N.; Angelucci, A.; Del Fattore, A.; Teti, A.; Zini, N.; Giunti, A.; Baldini, N. Bone-target doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases. Curr. Cancer Drug Targets, 2010, 10, 649-659.
114. Hilger, I.; Fruhauf, K.; Andra, W.; Hiergeist, R.; Hergt, R.; Kaiser, W.A. Heating potential of iron oxides for therapeutic purposes in interventional radiology Acad. Radiol., 2002, 9(2), 198-202.
115. Hilger, I.; Andra, W.; Hergt, R.; Hiergeist, R.; Schubert, H.; Kaiser, W.A. Electromagnetic heating of breast tumors in interventional radiology: in vitro and in vivo studies in human cadavers and mice. Radiology, 2001, 218(2), 570-575.
116. Milani, V.; Endres, M.; Kuppner, M.C.; Issels, R.D.; Noessner, E. Heat shock proteins, immune competence and vaccination. Dtsch. Med. Wochenschr., 2004, 129(1-2), 31-35.
117. Overgaard, J. The current and potential role of hyperthermia in radiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 1989, 16(3), 535-549.
118. Overgaard, J.; Gonzalez, D.; Hulshof, M.C.; Arcangeli, G.; Dahl, O.; Mella, O.; Bentzen, S.M. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. Lancet, 1995, 345(8949), 540-543.
119. Engelhardt, R. Hyperthermia and drugs. Recent Results Cancer Res., 1987, 104, 136-203.
120. Dewey, W.C. Arrhenius relationship from the molecule and cell to the clinic. Int. J. Hyperthermia, 1994, 10(4), 457-483.
121. Jain, P.K.; Huang, X.; El-Sayed, I.H.; El-Sayed, M.A. Noble metals on the nanoscale: optical and photothermal properties and some applications in imaging, sensing, biology, and medicine. Acc. Chem. Res., 2008, 41(12), 1578-1586.
122. Hainfeld, J.F.; Slatkin, D.N.; Smilowitz, H.M. The use of gold nanoparticles to enhance radiotherapy in mice. Phys. Med. Biol., 2004, 49, 309-315.
123. Clinicaltrials.gov: TNF-bound colloidal gold in treating patients with advanced solid tumors, in, 2010. http://clinicaltrials.gov/ct2/ show/NCT00356980 (Accessed January, 2010).
124. Clinicaltrials.gov: Pilot study of AuroLase(tm) therapy in refractory and/or recurrent tumors of the head and neck, in, National Institute of Health, 2010. http://clinicaltrials.gov/ct2/show/ NCT00848042. (Accessed January, 2010).
125. Loo, C.; Lowery, A.; Halas, N.J.; West, J.; Drezek, R. Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Lett., 2005, 5, 709-711.
126. Hirsch, L.R.; Stafford, R.J.; Bankson, J.A.; Sershen, S.R.; Rivera, B.; Price, R.E.; Hazle, J.D.; Halas, N.J.; West, J.L. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc. Natl. Acad. Sci. USA, 2003, 100, 13549-13554.
127. Schwartz, J.A.; Shetty, A.M.; Price, R.E.; Stafford, R.J.; Wang, J.C.; Uthamanthil, R.K.; Pham, K.; McNichols, R.J.; Coleman, C.L.; Payne, J.D. Feasibility study of particle-assisted laser ablation of brain tumors in orthotopic canine model. Cancer Res., 2009, 69, 1659-1667.
128. Huang, H.C.; Rege, K.; Heys, J.J. Spatiotemporal temperature distribution and cancer cell death in response to extracellular hyperthermia induced by gold nanorods. ACS Nano, 2010, 4(5), 2892-2900.
129. Jain, P.K.; Lee, K.S.; El-Sayed, I.H.; El-Sayed, M.A. Calculated absorption and scattering properties of gold nanoparticles of different size, shape, and composition: applications in biological imaging and biomedicine. J. Phys. Chem. B., 2006, 110, 7238-7248.
130. Huang, X.; Jain, P.K.; El-Sayed, I.H.; El-Sayed, M.A. Determination of the minimum temperature required for selective photothermal destruction of cancer cells with the use of immunotargeted gold nanoparticles. Photochem. Photobiol., 2006, 82, 412-417.
131. Lapotko, D. Therapy with gold nanoparticles and lasers: what really kills the cells? Nanomed., 2009, 4, 253-256.
132. Glazer, E.S.; Curley, S.A. Radiofrequency field-induced thermal cytotoxicity in cancer cells treated with fluorescent nanoparticles. Cancer, 2010 116(13), 3285-3293.
133. Elliott, A.M.; Shetty, A.M.; Wang, J.; Hazle, J.D.; Stafford, R. Use of gold nanoshells to constrain and enhance laser thermal therapy of metastatic liver tumours. Int. J. Hyperthermia, 2010, 26(5), 434-440.
134. Sato, A.; Tamura, Y.; Sato, N.; Yamashita, T.; Takada, T.; Sato, M.; Osai, Y.; Okura, M.; Ono, I.; Ito, A.; Honda, H.; Wakamatsu, K.; Ito, S.; Jimbow, K. Melanoma-targeted chemo-thermo-immuno (CTI)-therapy using N-propionyl-4-S-cysteaminylphenol-magnetite nanoparticles elicits CTL response via heat shock protein-peptide complex release. Cancer Sci., 2010, 101, 1939-1946.
135. Zhang, L.; Gu, F.X.; Chan, J.M.; Langer, R.S.; Farokhzad, O. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther., 2008, 83, 761-769.
136. Lee, B.S.; Park, K.; Park, S.; Kim, G.C.; Kim, H.J.; Lee, S.; Kil, H.; Oh, S.J.; Chi, D.; Kim, K.; Choi, K.; Kwon, I.C.; Kim, S.Y. Tumor targeting efficiency of bare nanoparticles does not mean the efficacy of loaded anticancer drugs: importance of radionuclide imaging for optimization of highly selective tumor targeting polymeric nanoparticles with or without drug. J. Control. Release, 2010, 147, 253-260.
137. Jiang, W.; Kim, B.Y.S.; Rutka, J.T.; Chan, W.C.W. Nanoparticle mediated cellular response is size-dependent. Nat. Nanotechnol., 2008, 3, 145-150.
138. Park, K.; Kim, J.H.; Nam, Y.S.; Lee, S.; Nam, H.Y.; Kim, K.; Park, J.H.; Kim, I.S.; Choi, K.; Kim, S.Y.; Wvon, I.C. Effect of polymer as molecular weight on the tumor targeting characteristics of self-assembled glycol chitosan nanoparticles. J. Control. Release, 2007, 122, 305-314.
139. Sznitowska, M.; Klunder, M.; Placzek, M. Paclitaxel solubility in aqueous dispersions and mixed micellar solutions of lecithin. Chem. Pharma Bull., 2008, 56, 70-74.
140. Foldbjerg, R.; Dang, D.A.; Autrup, H. Cytotoxicity and genotoxicity of silver nanoparticles in the human lung cancer cell line, A549. Arch. Toxicol., 2010, Apr 29. [Epub ahead of print]
141. Nel, A.; Xia, T.; Mädler, L.; Li, N. Toxic potential of materials at the nanolevel. Science, 2006, 311, 662-667.
142. Chen, Z.; Meng, H.; Xing, G.; Chen, C.; Zhao, Y.; Jia, G.; Wang, T.; Yuan, H.; Ye, C.; Zhao, F.; Chai, Z.; Zhu, C.; Fang, X.; Ma, B.; Wan, L. Acute toxicological effects of copper nanoparticles in vivo. Toxicol. Lett., 2006, 163, 109-120.
143. Cho, E.C.; Au, L.; Zhang, Q.; Xia, Y. The effects of size, shape, and surface functional group of gold nanostructures on their adsorption and internalization by cells. Small., 2009, 6, 517-522.
144. Sayes, C.M.; Reed, K.L.; Warheit, D.B. Assessing toxicity of fine and nanoparticles: Comparing in vitro measurements to in vivo pulmonary toxicity profiles. Toxicol. Sci., 2007, 97, 163-180.
145. Kim, J.S.; Yoon, T.J.; Yu, K.N.; Kim, B.G.; Park, S.J.; Kim, H.W.; Lee, K.H.; Park, S.B.; Lee, J.K.; Cho, M.H. Toxicity and tissue distribution of magnetic nanoparticles in mice. Toxicol. Sci., 2006, 89, 338-347.
146. Yang, S.T.; Fernando, K.A.S.; Liu, J.H.; Wang, J.; Sun, H.F.; Liu, Y.; Chen, M.; Huang, Y.; Wang, X.; Wang, H.; Sun, Y.P. Covalently PEGylated carbon nanotubes with stealth character in vivo. Small., 2008, 4, 940-944.
147. Goodman, C.M.; McCusker, C.D.; Yilmaz, T.; Rotello, V.M. Toxicity of gold nanoparticles functionalized with cationic and anionic side chains. Bioconjug. Chem., 2004, 15, 897-900.
148. Connor, E.E.; Mwamuka, J.; Gole, A.; Murphy, C.J.; Wyatt, M.D. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small., 2005, 1, 325-327.
149. Pernodet, N.; Fang, X.; Sun, Y.; Bakhtina, A.; Ramakrishnan, A.; Sokolov, J.; Ulman, A.; Rafailovich, M. Adverse effects of citrate/ gold nanoparticles on human dermal fibroblasts. Small., 2006, 2, 766-773.
150. Lewinski, N.; Colvin, V.; Drezek, R. Cytotoxicity of nanoparticles. Small., 2008, 4, 26-49.
151. Murphy, C.J.; Gole, A.M.; Stone, J.W. Gold nanoparticles in biology: Beyond toxicity to cellular imaging. Acc. Chem. Res., 2008, 41, 1721-1730.
152. Teeguarden, J.G.; Hinderliter, P.M.; Orr, G.; Thrall, B.D.; Pounds, J.G. Particokinetics in vitro: Dosimetry considerations for in vitro nanoparticle toxicity assessments. Toxicol. Sci., 2007, 95, 300-312.
153. Patra, H.K.; Banerjee, S.; Chaudhuri, U.; Lahiri, P.; Dasgupta, A. Cell selective response to gold nanoparticles. Nanomedicine, 2007, 3, 111-119.
154. Male, K.B.; Lachance, B.; Hrapovic, S.; Sunahara, G.; Luong, H.T. Assessment of cytotoxicity of quantum dots and gold nanoparticles using cell-based impedance spectroscopy. Anal. Chem., 2008, 80, 5487-5493.
155. Chithrani, B.D.; Ghazani, A.A.; Chan, W.C.W. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett., 2006, 6, 662-668.
156. Pan, Y.; Neuss, S.; Leifert, A.; Fischler, M.; Wen, F.; Simon, U.; Schmid, G.; Brandau, W.; Jahnen-Dechent, W. Size-dependent cytotoxicity of gold nanoparticles. Small, 2007, 3, 1941-1949.
157. Cho, W.S.; Kim, S.; Han, B.S.; Son, W.C.; Jeong, J. Comparison of gene expression profiles in mice liver following intravenous injection of 4 and 100 nm-sized PEG-coated gold nanoparticles. Toxicol. Lett., 2009, 191, 96-102.
158. Cho, W.S.; Cho, M.; Jeong, J.; Choi, M.; Cho, H.Y.; Han, B.S.; Kim, S.H.; Kim, H.O.; Lim, Y.T.; Chung, B.H.; Jeong, J. Acute toxicity and pharmacokinetics of 13 nm-sized PEG-coated gold nanoparticles. Toxicol. Appl. Pharmacol., 2009, 236, 16-24.
159. Zhang, G.; Yang, Z.; Lu, W.; Zhang, R.; Huang, Q.; Tian, M.; Li, L.; Liang, D.; Li, C. Influence of anchoring ligands and particle size on the colloidal stability and in vivo biodistribution of polyethylene glycol-coated gold nanoparticles in tumor-xenografted mice. Biomaterials., 2009, 30, 1928-1936.
160. Lipka, J.; Semmler-Behnke, M.; Sperling, R.A.; Wenk, A.; Takenaka, S.; Schleh, C.; Kissel, T.; Parak, W.J.; Kreyling, W.G. Biodistribution of PEG-modified gold nanoparticles following intratracheal instillation and intravenous injection. Biomaterials, 2010, 31, 6574-6581.
161. Zhang, X.D.; Wu, H.Y.; Di, W.; Wang, Y.Y.; Chang, J.H.; Zhai, Z.B.; Meng, A.M.; Liu, P.X.; Zhang, L.A.; Fan, F.Y. Toxicologic effects of gold nanoparticles in vivo by different administration routes. Int. J. Nanomedicine, 2010, 5, 771-781.
162. Yu, J.H.; Weng, Y.X.; Wang, X.S. The triplet excited state changes of amphiphilic porphyrins with different side-chain length in AOT reverse micelles. J Photochem Photobiol A, 2003, 156, 139-144.
163. Juarranz, A.; Jaen, P.; Sanz -Rodriguez, F.; Cuevas, J.; González, S. Photodynamic therapy of cancer. Basic principles and applications. Clin. Transl. Oncol., 2008, 10, 148-154.
164. Danson, S.; Ferry, D.; Alakhov, V.; Margison, J.; Kerr, D.; Jowle, D.; Brampton, M.; Halbert, G.; Ranson, M. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br. J. Cancer, 2004, 90, 2085-2091.
165. Shuai, X.; Ai, H.; Nasongkla, N.; Kim, S.; Gao, J. Micellar carriers based on block copolymers of poly(epsilon-caprolactone) and poly(ethylene glycol) for doxorubicin delivery. J. Control. Release, 2004, 98, 415-426.
166. Matsumura, Y.; Hamaguchi, T.; Ura, T.; Muro, K.; Yamada, Y.; Shimada, Y.; Shirao, K.; Okusaka, T.; Ueno, H.; Ikeda, M.; Watanabe, N. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br. J. Cancer, 2004, 91, 1775-1781.
167. Cohen, E.M.; Ding, H.; Kessinger, C.W.; Khemtong, C.; Gao, J.; Sumer, B.D. Polymeric micelle nanoparticles for photodynamic treatment of head and neck cancer cells. Otolaryngology - Head and Neck Surgery, 2010, 143, 109-115.
168. Camerin, M.; Magaraggia, M.; Soncin, M.; Jori, G.; Moreno, M.; Chambrier, I.; Cook, M.J.; Russell, D.A. The in vivo efficacy of phthalocyanine-nanoparticle conjugates for the photodynamic therapy of amelanotic melanoma. Eur. J. Cancer, 2010, 46(10), 1910-1918.
169. Hainfeld, J.F.; Slatkin, D.N.; Smilowitz, H.M. The use of gold nanoparticles to enhance radiotherapy in mice. Phys. Med. Biol., 2004, 49, 309-315.
170. Hainfeld, J.F.; Dilmanian, F.A.; Zhong, Z.; Slatkin, D.N.; Kalef-Ezra, J.A.; Smilowitz, H.M.; Gold nanoparticles enhance the radiation therapy of a murine squamous cell carcinoma. Phys. Med. Biol., 2010, 55(11), 3045-3059.
171. Shen, L.F.; Chen, J.; Zeng, S.; Zhou, R.R.; Zhu, H.; Zhong, M.Z.; Yao, R.J.; Shen, H. The superparamagnetic nanoparticles carrying the E1A gene enhance the radiosensitivity of human cervical carcinoma in nude mice. Mol. Cancer Ther., 2010, 9(7), 2123-2130.
172. Passarella, R.J.; Spratt, D.E.; van der Ende, A.E.; Phillips, J.G.; Wu, H.; Sathiyakumar, V.; Zhou, L.; Hallahan, D.E.; Harth, E.; Diaz, R. Targeted nanoparticles that deliver a sustained, specific release of Paclitaxel to irradiated tumors. Cancer Res., 2010, 70(11), 4550-4559.
173. French, J.T.; Goins, B.; Saenz, M.; Li, S.; Garcia-Rojas, X.; Phillips, W.T.; Otto, R.A.; Bao, A. Interventional Therapy of Head and Neck Cancer with Lipid Nanoparticle-carried Rhenium 186 Radionuclide. J. Vasc. Interv. Radiol., 2010, 21, 1271-1279.
174. Seneterre, E.; Taourel, P.; Bouvier, Y.; Pradel, J.; Van Beers, B.; Daures, J.P.; Pringot, J.; Mathieu, D.; Bruel, J.M. Detection of hepatic metastases: Ferumoxides-enhanced MR imaging versus unhenhanced MR imaging and CT during arterial portography. Radiology, 1996, 200, 785-792.
175. Mack, M.G.; Balzer, J.O.; Straub, R.; Eichler, K.; Vogl, T.J. Supermagnetic iron oxide-enhanced MR imaging of head and neck limph nodes. Radiology, 2002, 222, 239-244.
176. Harisinghani, M.G.; Barentsz, J.O.; Hahn, P.F.; Deserno, W.; de la Rosette, J.; Saini, S.; Marten, K.; Weissleder, R. MR lymphoangiography for detection of minimal nodal disease in patients with prostate cancer. Acad. Radiol., 2002, 9, 312-313.
177. Feldman, A.S.; McDougal, W.S.; Harisinghami, M.G. The potential of nanoparticle-enhanced imaging. Urol. Oncol., 2008, 26, 65-73.
178. Islam, T.; Harisinghani, M.G. Overview of nanoparticle use in cancer imaging. Cancer Biomark., 2009, 5, 61-67.
179. Chen, K.; Li, Z.; Wang, H.; Cai, W.; Chen, X. Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots. Eur. J. Nucl. Mol. Imaging, 2008, 35, 2235-2244.
180. Michalet, X.; Pinaud, F.F.; Bentolila, L.A.; Tsay, J.M.; Doose, S.; Li, J.J.; Sundaresan, G.; Wu, A.M.; Gambhir, S.S.; Weiss, S. Quantum dots for live cells, in vivo imaging, and diagnostics. Science, 2005, 307, 538-544.
181. Lee, H.Y.; Li, Z.; Chen, K.; Hsu, A.R.; Xu, C.; Xie, J.; Sun, S.; Chen, X. PET/MRI dual-modality tumor imaging using arginineglycine- aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J. Nucl. Med., 2008, 49, 1371-1379.
182. Baena, J.R.; Lendl, B. Ramam spectroscopy in chemical bioanalysis. Curr. Opin. Chem. Biol., 2004, 8, 534-539.
183. Qian, X.M.; Peng, X.H.; Ansari, D.O.; Yin-Goen, Q.; Chen, G.Z.; Shin, D.M.; Yang, L.; Young, A.N.; Wang, M.D.; Nie, S. In vivo tumor targeting and spectroscopic detection with surface-enhanced Ramam nanoparticle tags. Nat. Biotechnol., 2008, 26, 83-90.
184. Welsher, K.; Liu, Z.; Sherlock, S.P.; Robinson, J.T.; Chen, Z.; Daranciang, D; Dai, H. A route to brightly fluorescent carbon nanotubes for near-infrared imaging in mice. Nat. Nanotechnol., 2009, 4, 773-780.
185. Zavaleta, C.; de la Zerda, A.; Liu, Z.; Keren, S.; Cheng, Z.; Schipper, M.; Chen, X.; Dai, H.; Gambhir, S.S. Noninvasive Ramam spectroscopy in living mice for evaluation of tumor targeting with carbon nanotubes. Nano Lett., 2008, 8, 2800-2805.
186. Tang, C.; Russell, P.J.; Martiniello-Wilks, R.; Rasko, J.E.J.; Khatri, A. Concise review: Nanoparticles and cellular carriers-allies in cancer imaging and cellular gene herapy? Stem Cells, 2010, 28, 1686-1702.
187. Liu, Z.; Peng, R. Inorganic nanomaterials for tumor angiogenesis imaging. Eur. J. Nucl. Med. Mol. Imaging 2010, 37(Suppl 1), 147-163.
188. Copland, J.A.; Eghtedari, M.; Popov, V.L.; Kotov, N.; Mamedova, N.; Motamedi, M.; Oraevsky, A.A. Bioconjugated gold nanoparticles as a molecular based contrasdt agent: implication for imaging of deep tumors using optoacoustic tomography. Mol. Imaging Biol., 2004, 6, 341-349.
189. Yang, X.; Skrabalak, S.E.; Li, Z.Y.; Xia, Y.; Wang, L.V. Photoacustic tomography of a rat cerebral cortex in vivo with au nanocages as an optical contrast agent. Nano Lett., 2007, 7, 3798-3802.
190. De la Zerda, A; Zavaleta, C.; Keren, S.; Vaithilingam, S.; Bodapati, S.; Liu, Z.; Levi, J.; Smith, B.R.; Ma, T.J.; Oralkan, O.; Cheng, Z.; Chen, X.; Dai, H.; Khuri-Yakub, B.T.; Gambhir, S.S. Carbon nanotubes as photoacoustic molecular imaging agents in living mice. Nat. Nanotechnol., 2008, 3, 557-562.
191. Sharma, P.; Brown, S.C.; Bengtsson, N.; Zhang, Q., Walter, G.A.; Grobmyer, S.R.; Santa, S.; Jiang, H.; Scott, E.; Moudgil, B. Goldspeckled multimodal nanoparticles for noninvasive bioimaging. Chem. Mater., 2008, 20, 6087-6094.
192. Jun, Y.W., Huh, Y.M.; Choi, J.S.; Lee, J.H.; Song, H.T.; Kim, S.; Yoon, S.; Kim, K.S.; Shin, J.S.; Suh, J.S.; Cheon, J. Nanoscale size effect of magnetic nanocrystals and their utilization for cancer diagnosis via magnetic resonance imaging. J. Am. Chem. Soc., 2005, 127, 5732-5733.
193. Serda, R.E.; Godin, B.; Bianco, E.; Chiappini, C.; Ferrari, M. Multi-stage delivery nano-particle systems for therapeutic applications. Biochimica et Biophysica Acta, 2011, 1810(3), 317-29.
194. Blanco, E.; Hsiao, A.; Mann, A.P.; Landry, M.G.; Meric-Bernstam, F.; Ferrari, M. Nanomedicine in Cancer Therapy: Innovative Trends and Prospects. Cancer Sci., 2011, doi: 10.1111/j.1349- 7006.2011.01941.x.
195. Souza, G.S.; Staquicini, F.I.; Christianson, D.R.; Ozawa, M.G.; Miller, J.H.; Pasqualini, R.; Arap, W. Combinatorial targeting and nanotechnology applications. Biomed. Microdevices, 2010, 12(4), 597-606.
196. Chen, A.M.; Zhang, M.; Wei, D.; Stueber, D.; Taratula, O.; Minko, T.; He, H. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small, 2009, 5(23), 2673-2677.
197. Bale, S.S.; Kwon, S.J.; Shah, D.A.; Banerjee, A.; Dordick, J.S.; Kane, R.S. Nanoparticle-mediated cytoplasmic delivery of proteins to target cellular machinery. ACSNANO, 2010, 4, 1493-1500.
198. Flotte, T.R.; Carter, B.J. Adeno-associated virus vectors for gene therapy of cystic fibrosis. Methods in Enzymology., 1998, 292, 717-732.
199. Schatzlein, A.G. Non-viral vectors in cancer gene therapy: principles and progress. Anti-Cancer Drugs., 2001, 12(4), 275-304.
200. Liu, D.; Ren, T.; Gao, X. Cationic transfection lipids. Current Medicinal Chemistry, 2003, 10(14), 1307-1315.
201. Rettig, G.R.; Rice, K.G. Non-viral gene delivery: from the needle to the nucleus. Exp. Opin. Biol. Ther., 2007, 7(6), 799-808.
202. Montier, T.; Benvegnu, T.; Jaffrès, P-A.; Yaouanc, J-J.; Lehn, P. Progress in cationic lipid-mediated gene transfection: a series of bioinspired lipids as an example. Curr. Gene Ther., 2008, 8(5), 296-312.
203. Tanaka, T.; Mangala, L.S.; Vivas-Mejia, P.E.; Nieves-Alicea, R.; Mann, A.P.; Mora, E.; Han, H.D.; Shahzad, M.M.; Liu, X.; Bhavane, R.; Gu, J.; Fakhoury, J.R.; Chiappini, C.; Lu, C.; Matsuo, K.; Godin, B.; Stone, R.L.; Nick, A.M.; Lopez-Berestein, G.; Sood, A.K.; Ferrari, M. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res., 2010, 70(9), 3687-3696.
204. Wu, Y.; Wang, W.; Chen, Y.; Huang, K.; Shuai, X.; Chen, Q.; Li, X.; Lian, G. The investigation of polymer-siRNA nanoparticle for gene therapy of gastric cancer in vitro. Int. J. Nanomedicine, 2010, 5, 129-136.
205. Hee-Dong, H.; Mangala, L.S.; Lee, J.W.; Shahzad, M.M.; Kim, H.S.; Shen, D.Y.; Nam, E.J.; Mora, E.M.; Stone, R.; Lu, C.; Lee, S.J.; Roh, J.W.; Nick, A.M.; Lopez-Berestein, G.; Sood, A.K. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin. Cancer Res., 2010, 16(15), 3910-3922.
206. Bajaj, G.; Yeo, Y. Drug delivery systems for intraperitoneal therapy. Pharm. Res., 2010, 27(5), 735-738.
207. Rudolph, C.; Gleich, B.; Flemmer, A.W. Magnetic aerosol targeting of nanoparticles to cancer: nanomagnetosols. Methods Mol. Biol., 2010, 624, 267-280.
208. Zhao, L.; Feng, S.S. Enhanced oral bioavailability of paclitaxel formulated in vitamin E-TPGS emulsified nanoparticles of biodegradable polymers: in vitro and in vivo studies. J. Pharm. Sci., 2010, 99(8), 3552-3560.
209. Kim, D.; Jeong, Y.Y.; Jon, S. A Drug-Loaded Aptamer-Gold Nanoparticle Bioconjugate for Combined CT Imaging and Therapy of Prostate Cancer. ACS Nano, 2010, 4(7), 3689-3696.
210. Sekhon, B.S.; Kamboj, S.R. inorganic nanomedicine-Part 2. Nanomedicine, 2010, 6(5), 612-618.
211. Chen, B.A.; Jin, N.; Wang, J.; Ding, J.; Gao, C.; Cheng, J.; Xia, G.; Gao, F.; Zhou, Y.; Chen, Y.; Zhou, G.; Li, X.; Zhang, Y.; Tang, M.; Wang, X. The effect of magnetic nanoparticles of Fe3O4 on immune function in normal ICR mice. Int. J. Nanomedicine, 2010, 5, 593-599.
212. Li, P.W.; Kuo, T.H.; Chang, J.H.; Yeh, J.M.; Chan, W.H. Induction of cytotoxicity and apoptosis in mouse blastocysts by silver nanoparticles. Toxicol. Lett., 2010, 197(2), 82-87.
213. Gopinath, P.; Gogoi, S.K.; Sanpui, P.; Pul, A.; Chattopadhyay, A.; Ghosh, S.S. Signaling gene cascade in silver nanoparticle induced apoptosis. Colloids and Surfaces B: Biointerfaces, 2010, 77, 240-245.
214. Wang, X.; Qian, X.; Beitler, J.J.; Chen, Z.G.; Khuri, F.R.; Lewis, M.M.; Shin, H.J.; Nie, S.; Shin, D.M. Detection of circulating tumor cells in human peripheral blood using surface-enhanced Raman scattering nanoparticles. Cancer Res., 2011, 71(5), 1526-1532.
215. Nguyen, C.T.; Nguyen, J.T.; Rutledge, S.; Zhang, J.; Wang, C.; Walker, G.C. Detection of chronic lymphocytic leukemia cell surface markers using surface enhanced Raman scattering gold nanoparticles. Cancer Lett., 2010, 292(1), 91-97.
216. Estevez, M.C.; Huang, Y.F.; Kang, H.; O'Donoghue, M.B.; Bamrungsap, S.; Yan, J.; Chen, X.; Tan, W. Nanoparticle-aptamer conjugates for cancer cell targeting and detection. In: Cancer Nanotechnology, Methods in Molecular Biology 624, Grobmyer SR, Moudgil BM (eds). Springer Science+Business Media 2010; pp.235-247.
217. Herr, J.K.; Smith, J.E.; Medley, C.D.; Shangguan, D.; Tan, W. Aptamer-conjugated nanoparticles for selective collection and detection of cancer cells. Anal. Chem., 2006, 78, 2918-2924.
218. Smith, J.E.; Medley, C.D.; Tang, Z.; Shangguan, D.; Lofton, C.; Tan, W. Aptamer-conjugated nanoparticles for the collection and detection of multiple cancer cells. Anal. Chem., 2010, 79, 3075-3082.
219. Li, T.; Liu, D.; Wang, Z. Screening kinase inhibitors with a microarray-based fluorescent and resonance light scattering assay. Anal. Chem., 2010, 82(7), 3067-3072.
220. Moghimi, S.M.; Hunter, A.C.; Murray, J.C. (2001) Longcirculating and target-specific nanoparticles: Theory to practice. Pharmacol. Rev., 2001, 53, 283-318.
221. Decuzzi, P.; Pasqualini, R.; Arap, W.; Ferrari M. Intravascular delivery of particulate systems: Does geometry really matter? Pharm. Res., 2009, 26, 235-243.
222. Chaudhuri, P.; Harfouche, R.; Soni, S.; Hentschel, D.M.; Sengupta, S. Shape effect of carbon nanovectors on angiogenesis. ACS Nano, 2010, 4, 574-582.
223. Gratton, S.E.; Ropp, P.A.; Pohlhaus, P.D.; Luft, J.C.; Madden, V.J.; Napier, M.E.; DeSimone, J.M. The effect of particle design on cellular internalization pathways. Proc. Natl. Acad. Sci. USA 2008, 105, 11613-11618.
224. Yuan, F.; Dellian, M.; Fukumura, D.; Leunig, M.; Berk, D.A.; Torchilin, V.P.; Jain, R.K. Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size. Cancer Res., 1995, 55, 3752-3756.
225. Yuan, F.; Leunig, M.; Huang, S.K.; Berk, D.A.; Papahadjopoulos, D.; Jain, R.K. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res., 1994, 54, 3352-3356.
226. Northfelt, D.W.; Martin, F.J.; Working, P.; Volberding, P.A.; Russell, J.; Newman, M.; Amantea, M.A.; Kaplan, L.D. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: Pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J. Clin. Pharmacol., 1996, 36, 55-63.
227. Desai, N.; Trieu, V.; Yao, Z.; Louie, L.; Ci, S.; Yang, A.; Tao, C.; De, T.; Beals, B.; Dykes, D.; Noker, P.; Yao, R.; Labao, E.; Hawkins, M.; Soon-Shiong, P. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res., 2006, 12, 1317-1324.
228. Brown, S.C.; Palazuelos, M.; Sharma, P.; Powers, W.W.; Roberts, S.M.; Grobmyer, S.R.; Moudgil, B.M. Nanoparticle characterization for cancer nanotechnology and other biological applications. In: Cancer Nanotechnology, Methods in Molecular Biology 624, Grobmyer SR, Moudgil BM (eds), Springer+Business Media LLC, 2010; Chapter 4 pp 39-65.
229. Weizmann, Y.; Patolsky, F.; Katz, E.; Willner, I. Amplified DNA sensing and immunosensing by the rotation of functional magnetic particles. J. Am. Chem. Soc., 2003, 125(12), 3452-3454.
230. Song, H.T.; Choi, J.S.; Huh, Y.M.; Kim, S.; Jun, Y.W.; Suh, J.S.; Cheon, J. Surface modulation of magnetic nanocrystals in the development of highly efficient magnetic resonance probes for intracellular labeling. J. Am. Chem. Soc., 2005, 127(28), 9992-9993.
231. Gao, X.H.; Cui, Y.Y.; Levenson, R.M.; Chung LW, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol., 2004, 22(8), 959-960.
232. Chen, Y.; Yang, L.; Feng, C.; Wen, L.P. Nano neodymium oxide induces massive vacuolization and autophagic cell death in nonsmall cell lung cancer NCI-H460 cells. Biochem. Biophys. Res. Commun., 2005, 337(1), 52-60.
233. Zhang, L.; Zhang, K.; Prändl, R.; Schöffl, F. Detecting DNAbinding of proteins in vivo by UV-crosslinking and immunoprecipitation. Biochem. Biophys. Res. Commun., 2004, 322(3), 705-711.
234. Tokimoto, C. Cancer management: A multidisciplinary approach: Medical, surgical, and radiation oncology. In: Principles of Chemotherapy Pzadur R, editor. 8th ed. New York, NY: PPR; 2004.
235. Duguet, E.; Vasseur, S.; Mornet, S.; Devoisselle, J.M. Magnetic nanoparticles and their applications in medicine. Nanomedicine, 2006, 1, 157-168.
236. Dave, S.R.; Gao, X.H. Monodisperse magnetic nanoparticles for biodetection, imaging, and drug delivery: A versatile and evolving technology. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 2009, 1, 583-609.
237. Schroeder, U.; Sommerfeld, P.; Ulrich, S.; Sabel, B.A. Nanoparticle technology for delivery of drugs across the blood-brain barrier. J Pharm Sci., 1998, 87, 1305-1307.
238. Lin, B.L.; Shen, X.D.; Cui, S. Application of nanosized Fe3O4 in anticancer drug carriers with target-orientation and sustainedrelease properties. Biomed. Mater., 2007, 2, 132-134.